---

Block its recycling system, and cancer kicks the can, according to new Penn study

May 09, 2012

Potent new drug kills tumor cells in mice by clogging up their recycling system

PHILADELPHIA - All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have developed a potent new drug that clogs up the recycling machinery and kills tumor cells in mouse models.

Ravi K. Amaravadi, MD, assistant professor of Medicine, and colleagues showed previously that an old malaria drug, hydroxychloroquine, reduces autophagy in cancer cells and makes them more likely to die when exposed to chemotherapy. The strategy is currently being tested in clinical trials, and preliminary results are promising. The catch, though, is that it's not always possible to give patients a high enough dose of hydroxychloroquine to have an effect on their tumor cells.

Amaravadi teamed up with Jeffrey Winkler, PhD, the Merriam Professor of Chemistry, to design a series of more potent versions of chloroquine. They describe the design, chemical synthesis, and biological evaluation of a highly effective, new compound called Lys05, in the early edition of the Proceedings of the National Academy of Sciences this week.

Unlike hydroxychloroquine, which has little impact on tumor cells when used as a single agent, the new drug, called Lys05, slows tumor growth in animal models even in the absence of other anti-tumor therapies. What's more, the Lys05 dose that is toxic to cancer cells, which are addicted to recycling and rely on it much more heavily than healthy cells, has little or no effect on healthy cells.

"We see that Lys05 has anti-tumor activity at doses that are non-toxic for the animals," Amaravadi says. "This single-agent anti-tumor activity suggests this drug, or its derivative, may be even more effective in patients than hydroxychloroquine." Remarkably, however, when the investigators increase the dose of Lys05, some animals develop symptoms that mimic a known genetic deficiency in an autophagy gene, ATG16L1, which affects some patients with Crohn's disease . That similarity - technically called a phenocopy - clearly shows that Lys05 works by interfering with the recycling system in cells.

Lys05, and its companion compound Lys01, aren't quite ready for testing in patients, according to Amaravadi. Before that can happen, the molecules need to be optimized and undergo more toxicity testing in animals. Amaravadi and Winkler hope to team up with an industry partner for that portion of the project.

In the meantime, though, Amaravadi says the work illustrates just how important autophagy is to cancer cells, and provides an important new step for future therapies.


University of Pennsylvania School of Medicine

Related Hydroxychloroquine Current Events and Hydroxychloroquine News Articles

US study shows that tofacitinib is an efficacious treatment for active RA
Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent improvement in symptoms) when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group.

New approach to leukemia chemotherapy -- is a cure in sight?
Speaking at the UK National Stem Cell Network conference in York later today (31 March), Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia (CML) in which a small number of cancer cells persist despite effective therapy thus preventing cure.

Malaria drug slows pancreatic cancer growth in mouse models
Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis.

Expression of certain transporter proteins may predict resistance to drug therapy
he expression of a transporter protein called the Breast Cancer Resistance Protein (BCRP) in rheumatoid arthritis (RA) patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs (DMARDs), according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

Geisinger research: Antimalarial drug prevents diabetes in arthritis patients
The use of an antimalarial medication may prevent the onset of diabetes in patients with rheumatoid arthritis, new Geisinger research shows.

Common rheumatoid arthritis treatment shows potential for diabetes prevention
Far fewer rheumatoid arthritis patients treated with the drug hydroxychloroquine (HCQ) went on to develop diabetes compared to those who never took the drug.

Anti-malarial drug may reduce risk of diabetes for patients with rheumatoid arthritis
Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis

COST-EFFECTIVENESS ASSESSMENTS IMPORTANT FOR HIV RESPONSE IN AFRICA (p 1635)
A systematic review in this week's issue of THE LANCET highlights the importance of cost-effectiveness evaluation to identify realistic intervention programmes to tackle HIV/AIDS in Africa. HIV/AIDS accounts for around 20% of all deaths in Africa. The cost-effectiveness of interventions is important as African governments face difficult choices in striking the right balance between prevention, treatment, and care, all of which are necessary to deal with the HIV/AIDS epidemic. Andrew Creese from WHO, Geneva, Switzerland, and colleagues assessed existing data and their implications for value-for-money strategies to combat HIV/AIDS in Africa. The investigators identified over 60 reports that m

The Importance of Early Intervention in the Treatment of Rheumatoid Arthritis
Study Indicates that Even a Few Months Delay in Implementing Drug Therapy Increases Long-Term Disease Severity and Joint Damage       Findings Underscore the Urgency for Rapid Access of Patients to Specialist Care In a recent study, researchers found that the delay of treatment to patients with early Rheumatoid Arthritis (RA) significantly decreases the ability of traditional single-drug therapy to combat the disease`s debilitating symptoms. According to the study, which is published in the April 2002 issue of Arthritis & Rheumatism, a single-drug strategy is insufficient to achieve remission and prevent joint damage unless initiated at the onset of RA symptom

---

More Hydroxychloroquine Current Events and Hydroxychloroquine News Articles

---